IMPEL PHARMACEUTICALS INC (IMPL)
US45258K1097 - Common Stock
We assign a fundamental rating of 1 out of 10 to IMPL. IMPL was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of IMPL have multiple concerns. IMPL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IMPL had negative earnings in the past year.
In the past year IMPL has reported a negative cash flow from operations.
1.2 Ratios
With a Return On Assets value of -204.40%, IMPL is not doing good in the industry: 92.36% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.4% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-194.15%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 57.30%, IMPL belongs to the top of the industry, outperforming 80.07% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for IMPL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMPL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMPL has been increased compared to 1 year ago.
The debt/assets ratio for IMPL is higher compared to a year ago.
2.2 Solvency
IMPL has an Altman-Z score of -18.82. This is a bad value and indicates that IMPL is not financially healthy and even has some risk of bankruptcy.
IMPL's Altman-Z score of -18.82 is on the low side compared to the rest of the industry. IMPL is outperformed by 89.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.82 |
ROIC/WACCN/A
WACC10.15%
2.3 Liquidity
IMPL has a Current Ratio of 0.27. This is a bad value and indicates that IMPL is not financially healthy enough and could expect problems in meeting its short term obligations.
IMPL has a worse Current ratio (0.27) than 97.01% of its industry peers.
A Quick Ratio of 0.21 indicates that IMPL may have some problems paying its short term obligations.
The Quick ratio of IMPL (0.21) is worse than 97.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.50% over the past year.
The Revenue has grown by 264.05% in the past year. This is a very strong growth!
EPS 1Y (TTM)3.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q21.1%
Revenue 1Y (TTM)264.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q135%
3.2 Future
IMPL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.33% yearly.
The Revenue is expected to grow by 87.95% on average over the next years. This is a very strong growth
EPS Next Y64.5%
EPS Next 2Y34.33%
EPS Next 3Y23.19%
EPS Next 5Y21.33%
Revenue Next Year128.2%
Revenue Next 2Y101.18%
Revenue Next 3Y85.83%
Revenue Next 5Y87.95%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IMPL. In the last year negative earnings were reported.
Also next year IMPL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IMPL's earnings are expected to grow with 23.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.33%
EPS Next 3Y23.19%
5. Dividend
5.1 Amount
IMPL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMPEL PHARMACEUTICALS INC
NASDAQ:IMPL (12/15/2023, 7:00:03 PM)
After market: 0.22 -0.02 (-8.75%)0.2411
-0.17 (-41.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.76M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.4% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.3% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.21 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)3.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y64.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)264.05%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y